2 A4 o( C' @, x3 G0 E. T研究人员对3000多种分子进行了筛选,最终,他们发现NSC635437分子可阻止EWS-FLI1的融合蛋白与RHA相结合。这一发现是非常奇妙的,因为科学家们此前长期固有的概念是,蛋白质表面过于光滑以至于药物分子无法灵活地与之结合,相互作用是无法阻止的。. l4 p1 R" n4 F9 ^
' D; V/ i0 O3 n! ]5 x: W
之后,研究人员又设计出了一种更强的衍生化合物YK-4-279,将其在患有尤文氏肉瘤的两种动物模型上进行试验后,研究人员发现该药物可明显抑制肿瘤的生长。与非治疗组相比,使用YK-4-279治疗的动物模型,其肿瘤细胞减少了80%。1 d4 B# C' o8 |
' E) [$ q% j; h, g i k. |研究人员表示,虽然药物还需进行不断优化,但其已显示出抑制蛋白的相互作用或可作为一种只针对癌细胞的创新治疗方法。(生物谷Bioon.com) ( ^5 D3 t' v. O# C% L9 I# w . L& a) E; |+ r' i0 ~Nature Medicine 5 July 2009 | doi:10.1038/nm.1983 3 Q2 q- T+ ]( y g; l! [ 9 L- Q: y$ h1 mA small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma , T# G) q$ Z( M ; k+ W! |& l0 y" PHayriye V Erkizan1, Yali Kong1, Melinda Merchant2, Silke Schlottmann1, Julie S Barber-Rotenberg1, Linshan Yuan1, Ogan D Abaan1, Tsu-hang Chou2, Sivanesan Dakshanamurthy1, Milton L Brown1, Aykut üren1 & Jeffrey A Toretsky1,37 |5 \) x0 Z3 m
& }8 N: T* r1 _5 a
Abstract 0 I2 E; h. R, {* K + q- [/ e# ~, M0 {. |( eMany sarcomas and leukemias carry nonrandom chromosomal translocations encoding tumor-specific mutant fusion transcription factors that are essential to their molecular pathogenesis. Ewing's sarcoma family tumors (ESFTs) contain a characteristic t(11;22) translocation leading to expression of the oncogenic fusion protein EWS-FLI1. EWS-FLI1 is a disordered protein that precludes standard structure-based small-molecule inhibitor design. EWS-FLI1 binding to RNA helicase A (RHA) is important for its oncogenic function. We therefore used surface plasmon resonance screening to identify compounds that bind EWS-FLI1 and might block its interaction with RHA. YK-4-279, a derivative of the lead compound from the screen, blocks RHA binding to EWS-FLI1, induces apoptosis in ESFT cells and reduces the growth of ESFT orthotopic xenografts. These findings provide proof of principle that inhibiting the interaction of mutant cancer-specific transcription factors with the normal cellular binding partners required for their oncogenic activity provides a promising strategy for the development of uniquely effective, tumor-specific anticancer agents.$ j; l1 x- }6 W' Y2 j
; M0 E1 B* u! a! C2 |+ m
1 Georgetown University, Lombardi Comprehensive Cancer Center, Department of Oncology, Washington, DC, USA. % E. w. ?! O* ~% h2 Memorial Sloan-Kettering Cancer Center, New York, New York, USA. v( A' N; e! D+ v, O3 Georgetown University, Department of Pediatrics, Washington, DC, USA.作者: llingzu 时间: 2010-2-3 20:51